

## May 2017 APC Decisions

Medicine	Classification	Indication	Other Information
Adrenaline auto-injector (Emerade®)	GREEN	Anaphylaxis	Emerade® is available in 150 micrograms, 300 micrograms and 500 micrograms doses, whereas the other brands do not have a 500 microgram strength available. UK resuscitation guidelines recommend 500 micrograms for most patients over the age of 12 years
Prucalopride (Resolor®)	AMBER 2	Chronic constipation in men	At the time of its NICE TA, prucalopride was only licensed in women, since then the license has been extended based on new trial data. NICE do not plan to review their recommendation. Specialist initiation and review at 4 weeks
Opicapone (Ongentys®)	AMBER 2	Adjunctive therapy in Parkinson's disease	As a second line COMT inhibitor after entacapone.
Insulin glargine 300 units/ml (Toujeo®)	AMBER 2	Treatment of diabetes mellitus in adults	For patients that would otherwise receive insulin 500 units/ ml. Patients currently prescribed insulin 500 units/ ml may be actively reviewed and switched onto Toujeo® wherever possible under specialist supervision
Ethinylestradiol 30 mcg / drospirenone 3mg	GREEN	Contraception for those with intolerance	3rd/4th line agent in women who are intolerant to other progestogens. Recommending a branded generic version may decrease costs.
Acetylcysteine	GREY	Pulmonary fibrosis/ mucolytic	A licensed 200mg sachet is available preventing the import of the unlicensed product. This sachet increases the cost of treatment significantly and evidence is limited.
Glycopyrronium bromide 1mg/5ml	AMBER 2	Hypersalivation	Use of 1mg/5ml liquid would be off-label for this indication, however the 320 microgram /ml product requires dose conversion from current cBNF dose recommendations.

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

## News from the APC

### New to the APC website

- [Continance formulary and guideline](#) (update)
- [Diabetes guideline](#) (update)
- [Nebulised Colomycin guideline](#) (update)
- [Penicillin allergy awareness leaflet](#) (New)
- [Low Priority Medicines List](#) (Update)
- [Prescribing of GnRH analogues](#) (Update)
- [APC annual report 2016/17](#)

### Coming soon to the APC website

- [Ocular lubricants formulary](#) (new)
- [Antimicrobial Guideline](#) (Update)
- [DMARD Shared Care Protocols for Rheumatology](#) (Update)
- [Management of hyperlipidaemia in primary care guideline](#) (New)
- [Sip feeds guidelines](#) (update)
- [Buccal Midazolam in children guideline](#) (Update)

## Horizon Scanning, Formulary amendments and traffic light changes

### Formulary amendments

- Estradiol 0.06% gel - updated to **GREEN** in line with other HRT products
- Fosfomycin 3g sachets as the Monuril® brand - updated to **AMBER 3** in line with updated guidelines
- Xyloproct® updated to **GREY** and Scheriproct® changed to **GREEN** to reflect cost efficiency
- Strontium sachets reclassified to **GREY** following discontinuation
- Polycal® and RapiLOSE® updated to **GREEN** to allow use for GTT in primary care

### Current work in development

- Review of the HRT formulary chapter
- Farco-Fill® catheter solution (New submission)
- Glucodrate® rehydration solution (New submission)
- Colestipol for bile acid secretions (Evidence review)
- Omega 3 fatty acids (Evidence review)
- Update of formulary vaccines against national guidelines
- Emollient Formulary (Review)
- Laxative guidelines for adults (Review)
- Testosterone prescribing and monitoring information (New)
- Melatonin review of formulary status
- ADHD management in adults

### Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Parkinsons' Disease	Guideline	April 2017 - delayed
Chronic obstructive pulmonary disease – roflumilast	Technology Appraisal	June 2017
Etelcalcetide for treating secondary hyperparathyroidism	Technology Appraisal	June 2017
Hyperuricaemia (chronic) in gout - lesinurad	Technology Appraisal	July 2017
Familial hypercholesterolaemia	Guideline	August 2017
Obesity, overweight with risk factors - naltrexone-bupropion	Technology Appraisal	August 2017
Urinary tract infection in under 16s	Guideline	September 2017
Irritable bowel syndrome (diarrhoea) - eluxadoline	Technology Appraisal	September 2017
Endometriosis: diagnosis and management	Guideline	September 2017
Asthma management	Guideline	October 2017
Asthma diagnosis and monitoring	Guideline	October 2017
Glaucoma: diagnosis and management	Guideline review	October 2017

The work of the NAPC is supported and managed by the interface team below. They can be contacted via [nottsapc@nottspct.nhs.uk](mailto:nottsapc@nottspct.nhs.uk) if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Lynne Kennel, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust